deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT04084678

A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH (CAPACITY)

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy

Sponsor: United Therapeutics

Conditions Cardiovascular Diseases Connective Tissue Disease Familial Primary Pulmonary Hypertension Hypertension Hypertension, Pulmonary Lung Diseases PAH Pulmonary Arterial Hypertension Pulmonary Hypertension Respiratory Tract Disease Vascular Diseases
Interventions Placebo Ralinepag
Updated 31 times since 2019 Last updated: Oct 19, 2023 Started: Jan 20, 2021 Primary completion: Apr 12, 2023 Completion: Apr 12, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor decision

Other terminated trials from United Therapeutics

See all terminations from United Therapeutics

A PHASE3 clinical study on Cardiovascular Diseases and Connective Tissue Disease, this trial is terminated or withdrawn. The trial is conducted by United Therapeutics and has accumulated 31 data snapshots since 2021. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

~Oct 2019 – ~Mar 2020 · 5 months · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Aug 2020 · 2 months · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Apr 2022 · 4 months · monthly snapshot~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~Jun 2023 · 2 months · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Nov 2023 · 4 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 8 months · monthly snapshot

Change History

31 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Nov 2023 — Jul 2024 [monthly]

    Terminated PHASE3

    Status: Active Not Recruiting → Terminated

  5. Jul 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE3

▶ Show 26 earlier versions

  1. Jun 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE3

  2. Apr 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  3. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE3

  4. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE3

  5. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE3

  6. Sep 2022 — Jan 2023 [monthly]

    Recruiting PHASE3

  7. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  8. Apr 2022 — Jul 2022 [monthly]

    Recruiting PHASE3

  9. Dec 2021 — Apr 2022 [monthly]

    Recruiting PHASE3

  10. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  11. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

  12. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

  13. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  14. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE3

  15. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE3

  16. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

  17. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE3

  18. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  19. Dec 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE3

  20. Nov 2020 — Dec 2020 [monthly]

    Not Yet Recruiting PHASE3

  21. Oct 2020 — Nov 2020 [monthly]

    Not Yet Recruiting PHASE3

  22. Sep 2020 — Oct 2020 [monthly]

    Not Yet Recruiting PHASE3

  23. Aug 2020 — Sep 2020 [monthly]

    Not Yet Recruiting PHASE3

  24. Jun 2020 — Aug 2020 [monthly]

    Not Yet Recruiting PHASE3

  25. Mar 2020 — Jun 2020 [monthly]

    Not Yet Recruiting PHASE3

  26. Oct 2019 — Mar 2020 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • United Therapeutics
Data source: United Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Barcelona, Spain , Belo Horizonte, Brazil , Bialystok, Poland , Brussels, Belgium , Calgary, Canada , Chermside, Australia , Ciudad Autónoma de Bs. As., Argentina , Corrientes, Argentina , Denver, United States and 20 more locations